YiChang HEC ChangJiang Pharmaceutical : VOLUNTARY ANNOUNCEMENT FEBUXOSTAT TABLETS APPROVED TO LAUNCH

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

宜 昌 東 陽 光 長 江 藥 業 股 份 有 限 公 司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 01558)

VOLUNTARY ANNOUNCEMENT

FEBUXOSTAT TABLETS APPROVED TO LAUNCH

This announcement is made by YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (the ''Company'', together with its subsidiaries, the ''Group'') on a voluntary basis.

The board of directors (the ''Board'') of the Company is pleased to announce that Febuxostat Tablets (40mg and 80mg) (the ''Product'') acquired by the Company from Sunshine Lake Pharma Co., Ltd.* (廣東東陽光藥業有限公司) (''Sunshine Lake Pharma'') have undergone the assessment and approval process and obtained approval for launch from the China National Medical Products Administration. The marketing authorization holder of the Product is Dongguan Yangzhikang Pharmaceutical Co., Ltd.* (東莞市陽之康醫藥有限責 任公司) (''Yangzhikang''), a wholly-owned subsidiary of the Company.

Name of the drug (Chinese)	非布司他片	非布司他片
Name of the drug (English)	Febuxostat Tablets	Febuxostat Tablets
Form	Tablets	Tablets
Specification	40mg	80mg
Registration category	Type 3 Chemical Drug	Type 3 Chemical Drug
Handling number	CYHS1900363GUO	CYHS1900364GUO
Drug approval number	Guoyaozhunzi (國藥准字)	Guoyaozhunzi (國藥准字)
	H20213324	H20213325
Certificate number	2021S00442	2021S00443
Marketing authorization	Yangzhikang	Yangzhikang
holder

Febuxostat is used for the long-term treatment of hyperuricemia with the symptom of gout while it is not recommended for those suffering from hyperuricemia without clinical symptom. Febuxostat is a type of xanthine oxidase (XO) inhibitor which intends to lower serum uric acid concentration by inhibiting uric acid synthesization in order to get a satisfactory clinical result of treatment.

Febuxostat belongs to Class B (乙類品種) under the National Reimbursement Drug List for Basic Medical Insurance, Work-Related Injury Insurance, and Maternity Insurance (2020 version). According to the data from IQVIA, the sales amount of Febuxostat in China in 2020 was approximately USD198 million, representing an increase of 6.19% as compared to 2019.

- 1 -

The Product is a generic drug which obtained the approval for launch in China. After obtaining the approval for launch, it has been deemed to have passed the generic drug quality and efficacy consistency evaluation. The Product has high clinical value and favourable market prospects and will become one of the Company's products in the areas of endocrine and metabolic after its launch, which will further enrich the Group's product portfolio and will also provide patients with a choice of medication with high quality and fair price.

This announcement is made by the Company on a voluntary basis to keep investors informed of the latest business development of the Group, and contains no advertisement or intention regarding the use of any drug, surgical device, therapy or oral product.

On behalf of the Board

YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

TANG Xinfa

Chairman

Hubei, the PRC

14 May 2021

As at the date of this announcement, the Board consists of Mr. JIANG Juncai, Mr. WANG Danjin, Mr. CHEN Yangui and Mr. LI Shuang as executive directors; Mr. TANG Xinfa and Mr. Eddy HUANG as non-executive directors; and Mr. TANG Jianxin, Mr. ZHAO Dayao, Ms. XIANG Ling and Mr. LI Xuechen as independent non-executive directors.

- 2 -